SUMMARY The efficacy of treatment with spironolactone for congestive heart failure secondary to congenital heart disease was studied in 21 infants under 1 year of age. All received digoxin and chlorothiazide. In addition, group A (n = 10) was given supplements of potassium and group B (n = 11) received spironolactone. Daily clinical observations of vital signs, weight, hepatomegaly, and vomiting were recorded. Paired t test analysis showed significant reduction in liver size and weight (P< 01) and respiratory rate (P< 0 05) in group B, and less significant decreases in group A. The incidence of vomiting was slightly lower in group B. We conclude that the addition of spironolactone hastens and enhances the response to standard treatment with digoxin and chlorothiazide in infants with congestive heart failure.
Spironolactone, a pharmacological antagonist of the adrenal mineralocorticoid,l has been used for some years in the treatment of congestive heart failure (CHF). By competitively binding to specific nuclear macromolecules in the distal convoluted renal tubular cells, this agent inhibits aldosterone's regulatory effects on electrolytes, increasing sodium excretion and decreasing potassium excretion.2 Spironolactone is particularly effective in the treatment of patients with CHF who are taking diuretics, because it neutralises the kaliuretic effect of the thiazides and enhances natriuresis.
We have used spironolactone in the treatment of CHF for about 10 years at this hospital. However, its use in infants has been poorly documented. We therefore wished to compare the efficacy of spironolactone with that of a conventional potassium supplement, given in conjunction with digoxin and diuretic, in infants who had CHF secondary to congenital heart disease.
Patients and methods
Any infant aged under I year who was admitted to the cardiology ward and who had congenital heart defects with CHF that had been confirmed clinically and radiologically and by history and could not be controlled by the use of digitalis, or had not been treated, was considered for inclusion in the study. 
Study protocol
On entering the study, each infant was randomly allocated to one of the treatment regimens and was assigned an identification number. None entered the study more than once.
The infants were fed a routine ward diet of SMA 20, Enfalac milk, or 2 % milk, plus solids, juices, and commercial rice pablum* or baby foods, according to age. Types and volumes of intake were recorded on a diet-sheet and were summarised every 24 hours.
Clinical measurements were made daily at 0800 hours before being fed. The infants were weighed naked, each time on the same scales. Records of vital signs-blood pressure, respiratory rate, pulse rate, and temperature-were made while the infant was resting quietly, and therefore sometimes had to be postponed or omitted. These values were recorded at 0800 and 1600 hours, and at other times as necessary. Blood pressure was determined in standard manner by ausculation, using a Doppler ultrasound flow meter for the very small infants. Liver size below the right costal margin was measured through several respiratory cycles, by the same observer, with a paper tape along an imaginary line from the right nipple to the umbilicus; the average of these measurements was recorded as degree of hepatomegaly. Vomiting was recorded; > 15 ml was considered true vomitus volume, not just regurgitation. The time of vomiting, quality, quantity, and content were recorded.
A random urine sample was analysed for Na+ and K+ concentration each day. Plasma Na+, K+, Cl-, and HCO3-, and blood pH, Pco2, plasma urea, A dry cereal normally mixed with milk, similar to porridge or Farex. random plasma glucose, and the plasma digoxin level were determined twice weekly. The plasma level of digoxin was determined and an electrocardiogram was performed more often in the event of vomiting or cardiac dysrhythmia if this was thought to be due to digoxin toxicity.
All the data for each patient were recorded daily on flow-sheets. Values were calculated as mean± SEM. For each patient, each day the morning and afternoon respiratory and pulse rates were averaged, and liver size, respiration, pulse rate, and body weight were analysed by paired t tests and compared with day 1 findings. Student's t was used to determine significance of differences between the two groups.
At discharge, an appointment was made for the infant to be brought to the cardiology outpatient clinic. At that time the clinical history and assessment were again recorded together with vital signs, electrocardiograms, chest roentgenograrrs, and bloodchemistry values. If the infant was readmitted before the clinic visit, the new admission history and assessment were used for follow-up data.
Study patients
The study lasted 15 On entry into the study, group mean ages and heights did not differ appreciably but mean weight was significantly greater in group B than in group A (P<0.05). Mean daily weight fell for group B but not for group A (Fig. 1) . Paired t test analysis for day-by-day comparisons of individual patient's weights showed highly significant decreases (P<0 * 01) in group B (2.24 to 3.12%O) for the first 6 study days, while all patients were still in the study. In group A, significant decreases (2-59 to 3.12% (P<0-05)) occurred only on days 2, 4 (n = 10), and 7 (n = 8).
Initially, mean liver enlargement was comparable in the two groups (group A 3-85±0-248; group B 3 70±0 259 cm). Comparisons of daily means with day 1 showed significant decreases in hepatomegaly in both groups, particularly in group B (Fig. 2) Mean respiratory rate decreased significantly in both groups, rather erratically in group A (Fig. 3) . Statistically significant decrease in respiratory rates began on study day 4 in group B but not until day 6 in group A. The pulse rate decreased significantly (by Student's t test) on days 5, 7, and 8 in group B and not at all in group A (Fig. 4) . Fig. 4 Change in mean pulse rate compared with day 1, for each study day.
Fifteen vomiting episodes were recorded for each group, within 1 hour of ingestion of medication on 5 occasions in group A and on 3 occasions in group B. Seven of the 10 patients in group B and only 4 of the 11 patients in group A did not vomit, but there were no significant differences between groups (episodes of vomiting per day = 0a 148 in group A, and 0.124 in group B). There were no significant inter-or intragroup differences in plasma digoxin concentrations (range 0-8 to 4-0 in group A, and 0.8 to 3.9 ng/ml in group B; mean 1-96±0 196 and 1-92±0.111).
There was no significant difference for duration of time in the study; group A 10 1±1-62, group B 11 *0±0* 83 days. Three patients in each group left the study for surgical correction of cardiovascular defects. In group A, K-lyte was stopped for 4 infants because of lack of response of the CHF and was replaced by spironolactone, and 3 infants who were discharged to continue treatment (including K-lyte) were readmitted 6 to 24 days later, 2 
